vs
Phreesia, Inc.（PHR）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Ultragenyx Pharmaceutical Inc.的季度营收约是Phreesia, Inc.的1.7倍（$207.3M vs $120.3M），Phreesia, Inc.净利率更高（3.5% vs -62.0%，领先65.6%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 12.7%），Phreesia, Inc.自由现金流更多（$12.2M vs $-100.8M）
Phreesia, Inc.是一家SaaS服务企业，为医疗机构提供多款应用软件，帮助机构实现患者登记分诊流程的自动化处理与高效管理，助力医疗流程优化，提升机构运营效率与患者就诊体验。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
PHR vs RARE — 直观对比
营收规模更大
RARE
是对方的1.7倍
$120.3M
营收增速更快
RARE
高出13.2%
12.7%
净利率更高
PHR
高出65.6%
-62.0%
自由现金流更多
PHR
多$113.0M
$-100.8M
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $120.3M | $207.3M |
| 净利润 | $4.3M | $-128.6M |
| 毛利率 | — | — |
| 营业利润率 | 3.1% | -54.7% |
| 净利率 | 3.5% | -62.0% |
| 营收同比 | 12.7% | 25.9% |
| 净利润同比 | 129.7% | 3.5% |
| 每股收益（稀释后） | $0.07 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PHRRARE
| Q4 25 | $120.3M | $207.3M | ||
| Q3 25 | $117.3M | $159.9M | ||
| Q2 25 | $115.9M | $166.5M | ||
| Q1 25 | — | $139.3M | ||
| Q4 24 | — | $164.6M | ||
| Q3 24 | — | $139.5M | ||
| Q2 24 | — | $147.0M | ||
| Q1 24 | — | $108.8M |
净利润PHRRARE
| Q4 25 | $4.3M | $-128.6M | ||
| Q3 25 | $654.0K | $-180.4M | ||
| Q2 25 | $-3.9M | $-115.0M | ||
| Q1 25 | — | $-151.1M | ||
| Q4 24 | — | $-133.2M | ||
| Q3 24 | — | $-133.5M | ||
| Q2 24 | — | $-131.6M | ||
| Q1 24 | — | $-170.7M |
营业利润率PHRRARE
| Q4 25 | 3.1% | -54.7% | ||
| Q3 25 | -1.3% | -106.9% | ||
| Q2 25 | -2.8% | -64.8% | ||
| Q1 25 | — | -102.6% | ||
| Q4 24 | — | -74.3% | ||
| Q3 24 | — | -94.6% | ||
| Q2 24 | — | -79.1% | ||
| Q1 24 | — | -151.9% |
净利率PHRRARE
| Q4 25 | 3.5% | -62.0% | ||
| Q3 25 | 0.6% | -112.8% | ||
| Q2 25 | -3.4% | -69.0% | ||
| Q1 25 | — | -108.5% | ||
| Q4 24 | — | -80.9% | ||
| Q3 24 | — | -95.7% | ||
| Q2 24 | — | -89.5% | ||
| Q1 24 | — | -156.8% |
每股收益（稀释后）PHRRARE
| Q4 25 | $0.07 | $-1.28 | ||
| Q3 25 | $0.01 | $-1.81 | ||
| Q2 25 | $-0.07 | $-1.17 | ||
| Q1 25 | — | $-1.57 | ||
| Q4 24 | — | $-1.34 | ||
| Q3 24 | — | $-1.40 | ||
| Q2 24 | — | $-1.52 | ||
| Q1 24 | — | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $106.4M | $421.0M |
| 总债务越低越好 | $3.4M | — |
| 股东权益账面价值 | $320.3M | $-80.0M |
| 总资产 | $423.5M | $1.5B |
| 负债/权益比越低杠杆越低 | 0.01× | — |
8季度趋势，按日历期对齐
现金及短期投资PHRRARE
| Q4 25 | $106.4M | $421.0M | ||
| Q3 25 | $98.3M | $202.5M | ||
| Q2 25 | $90.9M | $176.3M | ||
| Q1 25 | — | $127.1M | ||
| Q4 24 | — | $174.0M | ||
| Q3 24 | — | $150.6M | ||
| Q2 24 | — | $480.7M | ||
| Q1 24 | — | $112.3M |
总债务PHRRARE
| Q4 25 | $3.4M | — | ||
| Q3 25 | $4.6M | — | ||
| Q2 25 | $6.2M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益PHRRARE
| Q4 25 | $320.3M | $-80.0M | ||
| Q3 25 | $298.0M | $9.2M | ||
| Q2 25 | $282.2M | $151.3M | ||
| Q1 25 | — | $144.2M | ||
| Q4 24 | — | $255.0M | ||
| Q3 24 | — | $346.8M | ||
| Q2 24 | — | $432.4M | ||
| Q1 24 | — | $140.3M |
总资产PHRRARE
| Q4 25 | $423.5M | $1.5B | ||
| Q3 25 | $408.6M | $1.2B | ||
| Q2 25 | $400.4M | $1.3B | ||
| Q1 25 | — | $1.3B | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | — | $1.5B | ||
| Q2 24 | — | $1.6B | ||
| Q1 24 | — | $1.3B |
负债/权益比PHRRARE
| Q4 25 | 0.01× | — | ||
| Q3 25 | 0.02× | — | ||
| Q2 25 | 0.02× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $15.5M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $12.2M | $-100.8M |
| 自由现金流率自由现金流/营收 | 10.1% | -48.6% |
| 资本支出强度资本支出/营收 | 2.7% | 0.5% |
| 现金转化率经营现金流/净利润 | 3.62× | — |
| 过去12个月自由现金流最近4个季度 | — | $-472.0M |
8季度趋势，按日历期对齐
经营现金流PHRRARE
| Q4 25 | $15.5M | $-99.8M | ||
| Q3 25 | $14.8M | $-91.4M | ||
| Q2 25 | $14.8M | $-108.3M | ||
| Q1 25 | — | $-166.5M | ||
| Q4 24 | — | $-79.3M | ||
| Q3 24 | — | $-67.0M | ||
| Q2 24 | — | $-77.0M | ||
| Q1 24 | — | $-190.7M |
自由现金流PHRRARE
| Q4 25 | $12.2M | $-100.8M | ||
| Q3 25 | $13.1M | $-92.7M | ||
| Q2 25 | $11.3M | $-110.7M | ||
| Q1 25 | — | $-167.8M | ||
| Q4 24 | — | $-79.5M | ||
| Q3 24 | — | $-68.6M | ||
| Q2 24 | — | $-79.0M | ||
| Q1 24 | — | $-193.9M |
自由现金流率PHRRARE
| Q4 25 | 10.1% | -48.6% | ||
| Q3 25 | 11.1% | -58.0% | ||
| Q2 25 | 9.8% | -66.5% | ||
| Q1 25 | — | -120.5% | ||
| Q4 24 | — | -48.3% | ||
| Q3 24 | — | -49.2% | ||
| Q2 24 | — | -53.7% | ||
| Q1 24 | — | -178.2% |
资本支出强度PHRRARE
| Q4 25 | 2.7% | 0.5% | ||
| Q3 25 | 1.5% | 0.8% | ||
| Q2 25 | 3.0% | 1.5% | ||
| Q1 25 | — | 1.0% | ||
| Q4 24 | — | 0.1% | ||
| Q3 24 | — | 1.2% | ||
| Q2 24 | — | 1.4% | ||
| Q1 24 | — | 3.0% |
现金转化率PHRRARE
| Q4 25 | 3.62× | — | ||
| Q3 25 | 22.68× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PHR
| Subscription And Services | $55.5M | 46% |
| Network Solutions | $37.4M | 31% |
| Payment Processing Fees | $27.4M | 23% |
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
